Creative Medical Technology
CELZ
9 hedge funds and large institutions have $267K invested in Creative Medical Technology in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
2.67% less ownership
Funds ownership: 7.8% → 5.14% (-2.7%)
31% less funds holding
Funds holding: 13 → 9 (-4)
52% less capital invested
Capital invested by funds: $552K → $267K (-$285K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$14.7K |
| 2 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
+$14.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.88K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$452 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$95 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$85K |
| 2 |
HF
HRT Financial
New York
|
-$68K |
| 3 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$57.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| 5 |
Two Sigma Investments
New York
|
-$403 |
CELZ Hedge Fund Activity: Q2 2024 in Review
9 of the 6,934 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q2 2024, worth a combined $267K — down 52% from $552K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CELZ and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Two Sigma Advisers, adding an estimated $14.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $85K sold.
- 9 institutional investors held Creative Medical Technology (CELZ) as of Q2 2024, down from 13 in Q1 2024.
- Funds reported $267K of Creative Medical Technology stock for Q2 2024, down 52% quarter-over-quarter.
- 1 fund opened new Creative Medical Technology positions in Q2 2024 and 5 closed out, a net change of -4 holders.
- The largest Creative Medical Technology buyer in Q2 2024 was Two Sigma Advisers, an estimated $14.7K added.
- The largest Creative Medical Technology seller in Q2 2024 was Virtu Financial, an estimated $85K sold.
Based on aggregated 13F filings for Q2 2024.